Nonclinical Development
BioMarin has a growing product pipeline with multiple drug candidates in the clinic and a promising collection of both internally developed and in-licensed preclinical programs now in development. The company’s preclinical development program begins with a tightly-managed early stage review process designed to maximize speed and efficiency around the identification and analysis of new product candidates for orphan diseases. By utilizing powerful, compelling biology, along with specialized manufacturing, clinical and regulatory expertise, BioMarin is providing rapid access to breakthrough drugs for patients who might otherwise go untreated.
Click on indications to learn more about each product candidate.
